Alnylampharmaceuticalsinc.gcs-web.com

Alnylam to Present Full 9-Month Results from the HELIOS-A Phase …

Web– Alnylam to Share Additional Data From its RNAi Product Portfolio Including ATTR Amyloidosis and Acute Hepatic Porphyria – –Company to Host Conference Call …

Actived: 8 days ago

URL: https://alnylampharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/alnylam-present-full-9-month-results-helios-phase-3-study

Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN …

Web– KARDIA-1 will Evaluate Efficacy and Safety of Quarterly and Biannual Regimens of Zilebesiran as Monotherapy – CAMBRIDGE, Mass.--(BUSINESS WIRE)- …

Category: Health Go Health

Alnylam Announces Launch of “Alnylam Challengers,” a Signature

Web− Alnylam will provide a $1 Million Grant to Acumen America and will serve as an Anchor Partner of their Health Equity Portfolio –. CAMBRIDGE, Mass.- …

Category: Health Go Health

Second Quarter 2021 Financial Results

WebGM as a % of Total Net Product Revenues for Q2 2021 is 81.2% and Q2 2020 is 76.4% (Q2 2021 and 2020 exclude $8.5M and $1.7M Cost of Collaborations and Royalties …

Category: Health Go Health

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational …

Webcardiovascular risk. About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in

Category: Health Go Health

Alnylam Announces 2023 Product and Pipeline Goals and …

WebCAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day …

Category: Health Go Health

First Set of Recommendations Advocating for the Holistic Care of …

WebNew study published in the BMJ Open calls for major shift in the management of hATTR amyloidosis. CAMBRIDGE, Mass. – [BUSINESS WIRE] – September 06, 2023 …

Category: Health Go Health

Alnylam Submits CTA Application for ALN-KHK, an Investigational …

WebCompany Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – CAMBRIDGE, Mass.--(BUSINESS WIRE)- …

Category: Health Go Health

Alnylam Submits CTA Application for ALN-XDH, an Investigational …

Web–Company Expects to Initiate a Phase 1/2 Study for ALN-XDH in Gout in Early 2022, with Initial Human Data in Late 2022 – CAMBRIDGE, Mass.--(BUSINESS …

Category: Health Go Health

Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

Web– Consistent Scientific Leadership Focused on Sustainable Innovation – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2022-- Alnylam Pharmaceuticals, Inc. …

Category: Health Go Health

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the …

WebCAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said …

Category: Health Go Health

First Quarter 2021 Financial Results

WebFitusiran. Hemophilia A or B, with and without inhibitors. ~200K. Patients WW with hemophilia A or B, with and without inhibitors. ~75% Patients switched to emicizumab …

Category: Health Go Health

New Clinical Results with Fitusiran

WebVenkat Living with Hemophilia New Clinical Results with Fitusiran 2017 International Society on Thrombosis and Haemostasis (ISTH) Congress July 10, 2017

Category: Health Go Health